David Turkaly, an analyst from JMP Securities, reiterated the Buy rating on TELA Bio (TELA – Research Report). The associated price ...

TELA Bio, Inc. (NASDAQ: TELA) has announced impressive financial results for the third quarter of 2024, achieving a record ...

The company said, “Reiterated full year 2024 revenue guidance of $74.5 million to $76.5 million, representing 27% to 31% year-over-year ...

The amount of the Tela Bio financing could grow by as much an additional $46 million. A Chester County medical technology company expects to raise $40 million in a stock sale this week.

The skies will be mostly cloudy. The high will reach 87° on this humid day. Good air quality (0-50) Primary pollutant O₃ 58 μg/m³ Pressure is the weight of the air in the atmosphere. It is normalized ...

TELA has been the subject of a number of research reports. Lake Street Capital reduced their target price on shares of TELA Bio from $14.00 to $8.00 and set a “buy” rating for the company in a ...

For Tela, there aren’t any characteristics of Trump’s masculinity that resonate with him. Trump’s comments about Haitian ...

TELA Bio (TELA) delivered earnings and revenue surprises of -13.51% and 0.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Everard Best met Téla D’Amore on the streets of New York City’s Lower East Side . Years later, the duo would helm a defining ...

TELA Bio, Inc. MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue ...

Gross profit was $12.9 million in the third quarter of 2024, or 68% of revenue, compared to $10.4 million, or 69% of revenue, in the same period in 2023. The decrease in gross margin was primarily due ...

Full Year Revenue Guidance: $74.5 million to $76.5 million for 2024, reflecting growth of 28% to 31% over 2023. TELA Bio Inc ...